Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response - Schneider, Bryan J.; Shah, Manish A.; Klute, Kelsey; Ocean, Allyson; Popa, Elizabeta; Altorki, Nasser; Lieberman, Michael; Schreiner, Andrew; Yantiss, Rhonda; Christos, Paul J.; Palmer, Romae; You, Daoqi; et al. (Clinical cancer research, 2017)
Keywords: Adenocarcinoma; Adenocarcinoma - drug therapy; Adenocarcinoma - genetics; Adenocarcinoma - pathology; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Azacitidine - administration & dosage; Bioindicators; Biomarkers; Bisulfite; Cancer; Chemotherapy; Cisplatin - administration & dosage; Deoxyribonucleic acid; DNA; DNA methylation; DNA Methylation - genetics; Dose-Response Relationship, Drug; Epigenesis, Genetic - genetics; Epigenetics; Epirubicin; Epirubicin - administration & dosage; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - genetics; Esophageal Neoplasms - pathology; Esophagus; Experimental design; Female; Fluorouracil - administration & dosage; Genes; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds - administration & dosage; Oxaliplatin; Patients; Priming; Stomach Neoplasms - drug therapy; Stomach Neoplasms - genetics; Stomach Neoplasms - pathology; Surgery; Toxicity; Tumor suppressor genes; Tumor Suppressor Proteins - drug effects; Tumor Suppressor Proteins - genetics